Home

How

History

Auto

pubs

   Current
   Pre-1999 Archives


patents

contact

FAQ

links

  Site Map

Publication Abstracts

GeneSwitch® papers

Ruxandra Draghia-Akli, P. Brandon Malone, Leigh Anne Hill, Kenneth M. Ellis, Robert J. Schwartz, and Jeffrey L. Nordstrom. Enhanced animal growth via ligand-regulated GHRH myogenic-injectable vectors. FASEB J 2002 Mar;16(3):426-8 - Studies that demonstrate growth pattern and body composition can be efficiently regulated after the delivery of a plasmid-based, mifepristone-inducible GHRH expression system.

Osterwalder T, Yoon KS, White BH, Keshishian H. A conditional tissue-specific transgene expression system using inducible GAL4. Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12596-601. - Demonstrate the applicability of the GeneSwitch® system (version 3.1) for conditional tissue-specific expression in Drosophila.

Roman G, Endo K, Zong L, Davis RL. P[Switch], a system for spatial and temporal control of gene expression in Drosophila melanogaster. Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12602-7. - Developed a method for turning on and off the expression of transgenes within Drosophila in both time and space.

Terada Y, Tanaka H, Okado T, Inoshita S, Kuwahara M, Akiba T, Sasaki S, Marumo F. Efficient and ligand-dependent regulated erythropoietin production by naked DNA injection and in vivo electroporation. Am J Kidney Dis. 2001 Oct;38(4 Suppl 1):S50-3. - Describes regulated Epo expression by the autoinducible GeneSwitch® system (version 3.1) in rats after naked DNA injection followed by electroporation.

Pierson TM, Wang Y, DeMayo FJ, Matzuk MM, Tsai SY, Omalley BW. Regulable expression of inhibin A in wild-type and inhibin alpha null mice. Mol Endocrinol. 2000 Jul;14(7):1075-85. - Describes studies that are the first example of an inducible system (GeneSwitch® version 2.0) being used to prevent a lethal knockout phenotype in an animal model.

Abruzzese RV, Godin D, Mehta V, Perrard JL, French M, Nelson W, Howell G, Coleman M, O'Malley BW, Nordstrom JL. Ligand-dependent regulation of vascular endothelial growth factor and erythropoietin expression by a plasmid-based autoinducible GeneSwitch system. Mol Ther. 2000 Sep;2(3):276-287. - Describes the ability of an autoinducible GeneSwitch® system (version 3.1) to regulate VEGF and Epo in vivo in a drug-dependent manner.

Abruzzese, R.V., Godin, D., Burcin, M.M., Mehta, V., French, M., Li, Y., O'Malley, B.W. and Nordstrom, J.L. (1999). Ligand-dependent regulation of plasmid-based transgene expression in vivo. Hum. Gene Ther. 10, 1499-1507. - Describes the first in vivo gene therapy studies with the plasmid-based GeneSwitch® system (version 3.1).

Wang, X.J., Liefer, K.M., Tsai, S.Y., O’Malley, B.W. and Roop, D.R. (1999). Development of gene-switch transgenic mice that inducibly express transforming growth factor beta1 in the epidermis. Proc. Natl. Acad. Sci. USA 96, 8483-8488. - Demonstrates an application for the GeneSwitch® system in transgenic mice and topical administration of MFP.

Burcin, M.M., Schieder, G., Kochanek, S., Tsai, S.Y. and O’Malley, B.W. (1999). Adenovirus-mediated regulatable target gene expression in vivo. Proc. Natl. Acad. Sci. USA 96, 355-360. - Describes first adenoviral GeneSwitch® system (version 3.0) and demonstrates its ability to regulate hGH in vivo.

Review articles

Smith, L.C. and Nordstrom, J.L. (2000). Advances in plasmid gene delivery and expression in skeletal muscle. Curr. Opin. in Mol. Thera. 2(2), 150-154.

Chua, S.S., Burcin, M.M., Wang, Y. and Tsai, S.Y. (1999). A novel gene regulatory system. Nonviral Vectors for Gene Therapy (Acad. Press).